Peptide therapy
By Dr. K.D. LanierJuly 29, 2026 · Clinical review required before public release
Begin with the exact purpose
“Peptide” describes a broad group of short amino-acid chains, not one treatment. Ask for the exact name of the proposed therapy, the health goal it is intended to address, and why it is being considered for you.
A symptom or wellness goal may have more than one explanation. Your history helps the provider understand the request before any product is considered.
Ask what the evidence actually shows
The amount and quality of human evidence vary widely by peptide and proposed use. Ask whether the recommendation is supported by an FDA-approved indication, an off-label use of an approved drug, limited clinical research, or evidence that remains preliminary.
Evidence for one peptide, dose, route, or condition should not be assumed to apply to another.
Understand approved, off-label, and compounded options
An FDA-approved drug has been reviewed for safety, effectiveness, and manufacturing quality for its approved use. A licensed clinician may sometimes prescribe an approved drug for a different, off-label use when medically appropriate.
Compounded drugs are not FDA-approved and are not the same as FDA-approved generic drugs. Compounding may meet an individual medical need in certain circumstances, but product source, quality controls, and the reason an approved option cannot meet that need should be discussed clearly.
Review candidacy and interactions
Your provider should review medical conditions, allergies, pregnancy or breastfeeding considerations, current prescriptions, over-the-counter products, supplements, prior reactions, and relevant laboratory information.
Ask which factors would make the therapy unsuitable, which interactions are known or uncertain, and whether another evaluation is needed first.
Clarify administration, handling, and sourcing
Ask how the therapy is administered, how the dose is determined, how it should be stored, what to do after a missed dose, and which symptoms require a call to the care team.
For any compounded product, ask which licensed pharmacy prepares it and how the provider verifies the source. Do not use products labeled for research use only or obtained outside an appropriate prescription pathway.
Discuss risks without minimizing uncertainty
No peptide therapy is universally safe. Potential side effects, immune reactions, contamination or dosing concerns, interactions, and product-specific unknowns should be reviewed before treatment.
Some bulk peptide substances have limited human safety data or have been identified by FDA as presenting potential significant safety risks. The exact substance matters.
Define monitoring before the first dose
Ask what baseline information is needed, which symptoms or measurements will be monitored, when follow-up occurs, and what would lead the provider to adjust or stop the plan.
A refill depends on provider review, response, tolerability, and continued appropriateness. Every request receives a fresh decision.
Questions to take into the consultation
A good conversation should leave you able to name the exact therapy, its proposed purpose, the strength of evidence, its regulatory status, the source of the product, the likely costs, the important risks, the alternatives, and the follow-up plan.
- Is this product FDA-approved for this use, used off-label, or compounded?
- What evidence supports this recommendation for someone with my history?
- What risks, interactions, and unknowns should I understand?
- Where will the product come from, and how should it be handled?
- How will we monitor response, side effects, and refill eligibility?
Sources and current guidance
Regulatory status and safety information can change. These FDA resources provide current context for questions about compounded drugs and selected bulk peptide substances.